Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMETHYST: Verinurad + Allopurinol in HFpEF
NCT04327024Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of verinurad in heart failure with preserved ejection fraction (HFpEF), sponsored by AstraZeneca. Started May 2020; status: completed.
02
Drugs
verinurad
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT04327024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04327024.